The global benign prostatic hyperplasia treatment market is to increase from US$ 10,790 million in 2020 to US$ 13,978 million by 2025 with a compound annual growth rate (CAGR) of 5.3% for the period 2020-2025. BPH, a non-malignant growth of prostate tissue, is frequently responsible for lower urinary tract symptoms in men. The hormonal production of testosterone and dihydrotestosterone are required for the development of BPH, which is thought to be a normal part of male aging (DHT). By the age of 60, almost half of men have histopathologic BPH, and 90% have it by the age of 85. Over 30 million men worldwide, including 14 million in the United States, are thought to have BPH symptoms According to statistics from the Health Insurance Review and Assessment (HIRA) organization in 2018, BPH was diagnosed in approximately 7,600,000 people in 2010, and an increase of 1.2 million from the previous year. This implies a 7% annual growth rate and a 58% cumulative growth rate since 2010.
Because BPH is a common disease that affects men as they age, the growing elderly population, particularly the geriatric male population, may be considered a significant contributor to the incidence of BPH. As a result, the growth of this generation will ensure that effective therapies are in high demand in important markets. For example, China is expected to have the highest proportion of elderly people in the world; by 2050, that proportion is expected to rise from 10.1% to 26.8% of the total population. (Source: US Bureau of the Census) According to WHO estimates, China will have 100 million people aged 80 and up by 2050. According to the NHS, there were five million men in the UK in 2019, but that number is expected to rise to seven million by 2030 and over nine million by the end of 2050.
One of the key market trends expected to benefit the sector over the forecast period is the increasing demand for office-based minimally invasive surgical procedures. The majority of newly developed minimally invasive procedures can be performed as outpatient procedures or in the doctor's office. In-office BPH treatments can be completed in about an hour without the use of general anesthesia. These procedures are appropriate for people who do not want to take daily medications for the rest of their lives while also avoiding ongoing pharmaceutical costs, side effects, and the high costs of invasive surgeries. The vast majority of patients and doctors prefer in-office BPH treatment.
Some of the prominent players in the benign prostatic hyperplasia treatment market are Allergan Plc, Asahi Kasei Corporation, Asclepion Laser Technologies Gmbh, Astellas Pharma Inc., Biolitec Ag, Boston Scientific Corporation, Coloplast Group, Eli Lilly, Glaxosmithkline Plc, Ipg Photonics Corporation. The research report on the global benign prostatic hyperplasia treatment market provides extensive competition analysis and competitive conditions. The report includes information on significant products, players, challenges and developments, and other information specific to the benign prostatic hyperplasia treatment market. The global economy is highly affected by the COVID-19. Various sectors in the economy are much affected by this pandemic. It is anticipated that the global economy will decline because of the loss of trillions of dollars. The growing extension and imposition of lockdown in various countries directly affect the economy all over the world. The report consists of a chapter that provides a detailed study of the impact of COVID-19 on the benign prostatic hyperplasia treatment market. The data in this report is targeted for business and industry practitioners and specifically intended to assist in the explanation, direction, and to understand the potential of the benign prostatic hyperplasia treatment markets. The study focuses on providing readers with an understanding of developments in the industry, market segments, market forecasts, leading players, and market drivers and inhibitors.
- Goals and objectives of the study
- Understanding the opportunities and advancements of benign prostatic hyperplasia treatment is determining the market highlights, along with the foremost regions and countries involved in the growth of the market.
- To study the diverse segments of the benign prostatic hyperplasia treatment market and the dynamics of benign prostatic hyperplasia treatment in the market.
- To categorize segments of benign prostatic hyperplasia treatment with escalating growing potential and to value the futuristic market of the segments.
- To analyze the major trends related to different segments that help in figuring and persuading the benign prostatic hyperplasia treatment market.
- To check region-specific growth and development in the benign prostatic hyperplasia treatment market.
- To understand the foremost stakeholders of the benign prostatic hyperplasia treatment market and the value of the competitive landscape of the leaders of the benign prostatic hyperplasia treatment market.
- To study the key plans, initiatives, and strategies for the development of the benign prostatic hyperplasia treatment market.
Chapter 2, Market Overview provides an overview of the benign prostatic hyperplasia treatment market. The chapter includes macro-economic factors, market determinants (includes market drivers, restraints, opportunities, and challenges), value chain analysis, technology/product roadmap, Porter 5 force model analysis, market growth opportunity analysis.
Chapter 3, Segment Analysis of the study deals with the different sub-segments of the market to calculate reliable market forecasts. The chapter provides an in-depth analysis of the market segments of the benign prostatic hyperplasia treatment market, year-on-year growth projections that enable readers to identify potential market growth areas.
- Market Segmentation
- Based on type, the global benign prostatic hyperplasia treatment market is segmenting into drug treatment, surgical treatment.
- Based on end user, the benign prostatic hyperplasia treatment market is segmenting into home healthcare, hospitals & clinics.
Chapter 4, Regional Analysis includes an in-depth analysis of the benign prostatic hyperplasia treatment market by regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. The report also includes a comprehensive analysis of the market in key countries such as the United States, Canada, Germany, France, Italy, Spain, China, India, Japan, the GCC, South Africa, Brazil, Mexico, and the rest of the world. Regional insight helps market competitors to make crucial decisions about their company. Individualized, country-wise, and segment-wise analyses by region allow readers of the benign prostatic hyperplasia treatment market report to explore the potential of the market in different geographies. For each year's growth projections and a global share of value, this section is a vital part of the report.
Chapter 5, Competitive Analysis of the report includes company shares analysis, a list of acquisitions, mergers, collaboration, and the introduction of new products.
Chapter 6, Company Profile of the report also covers key industry players working on the benign prostatic hyperplasia treatment market. The report also discusses the business strategies adopted by the players at the global, regional, and country-level. The study also focuses on various businesses or inorganic business development strategies for expanding consumer networks through product formation, organization extension, partnerships, mergers, and acquisitions.
The study offers an exhaustive summary and estimate of the global benign prostatic hyperplasia treatment market. It includes in-depth qualitative and quantitative analyses in the report that aligned with the goals and objectives of our customers. Projections have been confirmed by comprehensive primary and secondary analysis. The study will encourage clients to invest in the benign prostatic hyperplasia treatment market based on the current business situation, trends, and potential developments in the segments. Understanding the requirement of the client, the report delivers specialist insights into the global benign prostatic hyperplasia treatment market, its products, and market patterns.
